Free Trial
NASDAQ:MRUS

Merus Q1 2025 Earnings Report

Merus logo
$66.10 -1.18 (-1.75%)
Closing price 04:00 PM Eastern
Extended Trading
$64.39 -1.71 (-2.59%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus EPS Results

Actual EPS
-$2.23
Consensus EPS
-$1.17
Beat/Miss
Missed by -$1.06
One Year Ago EPS
N/A

Merus Revenue Results

Actual Revenue
$8.83 million
Expected Revenue
$9.77 million
Beat/Miss
Missed by -$940.00 thousand
YoY Revenue Growth
N/A

Merus Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Merus' Q3 2025 earnings is scheduled for Thursday, October 30, 2025, with a conference call scheduled on Friday, October 31, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Merus Earnings Headlines

Merus to Present at the 2025 Wells Fargo Healthcare Conference
Merus (NASDAQ:MRUS) Coverage Initiated at Alliance Global Partners
The stealth altcoin the financial world is underestimating
This DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening RIGHT NOW—this project is poised to see massive moves.... The smart money is already positioning.tc pixel
See More Merus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merus and other key companies, straight to your email.

About Merus

Merus (NASDAQ:MRUS), a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

View Merus Profile

More Earnings Resources from MarketBeat